 |
|
|
|
|
|
 |
 |
 |
 |
 |
 |
|
||||||||||||||||||||
Title: |
Worldwide Survey of the Results of Treating Gestational Trophoblastic Disease | |||||||||||||||||||
| Authors: | Ernest I. Kohorn, M.A., M.Chir. (Cantab), F.R.C.S., F.R.C.O.G., F.A.C.O.G. | |||||||||||||||||||
|
OBJECTIVE: To determine factors influencing outcome for patients with gestational trophoblastic disease (GTD) from throughout the world. STUDY DESIGN: Physicians known to treat GTD were sent a questionnaire. RESULTS: There were 32 responses from 17 countries, totaling 26,153 patients. Of 14,093 patients with complete mole 20.6% developed trophoblastic neoplasia, and 5.7% died. There were 10,230 patients with partial mole, of whom 6.5% received thera-py for neoplasia. There were 548 patients with post–term pregnancy choriocarcinoma, of whom 13.4% died. Of 137 patients with placental site trophoblastic tumor 16.1% died. The remaining 1,165 patients did not fit into a designated diagnostic category. The mortality rate for 2,818 patients with GTD primarily treated at a trophoblast center was 2.1%, as compared with 8% among 1,854 patients referred after failure of primary treatment (p<0.01). CONCLUSION: Patients treated by physicians experienced in the management of trophoblastic disease have better results and survival. |
||||||||||||||||||||
| Keywords: | choriocarcinoma, complete mole, gestational trophoblastic disease, molar pregnancy, partial mole, placental site trophoblastic tumor | |||||||||||||||||||
| Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from  |
||||||||||||||||||||
